Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Brune Akrich, MD

Associate Director Medical Affairs
Merck Research Labs, MSD, France

Disclosure(s): Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck., Stocks/Bonds (Public Company)

Poster(s):

(P-1074) Clinical Outcomes in Patients Hospitalized with Exacerbation of Chronic Respiratory Infections treated with Ceftolozane/Tazobactam: Results from SPECTRA

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1076) Describing the clinical characteristics, treatment patterns, and outcomes in hospitalized pneumonia patients treated with Ceftolozane/Tazobactam (C/T): Insights from the SPECTRA Study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1113) Treatment Patterns and Clinical Outcomes in Hospitalized Patients with Febrile Neutropenia treated with Ceftolozane/Tazobactam: A Subgroup Analysis of the SPECTRA study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients

Saturday, October 19, 2024
12:15 PM – 1:30 PM US PT